CA2206743C - Endoprosthesis assembly for percutaneous deployment and method of deploying same - Google Patents
Endoprosthesis assembly for percutaneous deployment and method of deploying same Download PDFInfo
- Publication number
- CA2206743C CA2206743C CA002206743A CA2206743A CA2206743C CA 2206743 C CA2206743 C CA 2206743C CA 002206743 A CA002206743 A CA 002206743A CA 2206743 A CA2206743 A CA 2206743A CA 2206743 C CA2206743 C CA 2206743C
- Authority
- CA
- Canada
- Prior art keywords
- sleeve
- range
- expanded
- assembly
- inner diameter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
Abstract
The present invention provides an endoprosthesis assembly having a reduced cross sectional profile for percutaneous deployment and implantation within a body passageway such as a blood vessel. The assembly comprises a radially expandable cylindrical frame having first and second ends, and a first unexpanded outer diameter and a second expanded outer diameter. The assembly further comprises a radially expandable elastomeric sleeve surrounding a length of the frame and having first and second ends and a first unexpanded inner diameter and a second expanded inner diameter. The inner diameter of the expanded sleeve is not greater than the outer diameter of the expanded frame. The second expanded inner diameter of the sleeve is in a range from about 60% to about 380% greater than the first unexpanded inner diameter of the sleeve. The assembly of the preferred embodiment is adapted to be deployed through an introducer smaller than 9 French and the sleeve is capable of expanding to an inner diameter of about 12 millimeters.
Description
ENDOPROSTHESIS ASSEMBLY FOR PERCUTANEOUS DEPLOYMENT
AND METHOD OF DEPLOYING SAME
Field of the Invention This invention generally relates to an endoprosthesis assembly for percutaneous deployment and implantation into a blood vessel or other hollow body passageway, and a method for deploying an endoprosthesis assembly. More particularly, the invention relates to an assembly comprising a frame surrounded by an elastomeric sleeve, where the assembly has a reduced profile for percutaneous deployment.
Background of the Invention Various endoprostheses, or stems, have been proposed or developed for use in association with angioplasty treatments and other medical procedures wherein devices having expandable components are used to treat a condition within a body passageway such as a blood vessel. The stent is typically cylindrical or tubular in shape and has an open construction such as a scaffold, or frame. Stents are constructed so as to be radially collapsible. They are also radially expandable using techniques such as the introduction of a radially projecting force from inside the stent.
Stents for implantation into a blood vessel, artery or the like to maintain or restore the patency of the passageway have been deployed percutaneously to minimize the invasiveness associated with surgical exposure of the treatment site.
Percutaneous .
deployment is initiated by an incision into the vasculature of the patient, typically into ' the femoral artery. An introducer comprising a cylinder open at each end is disposed across the incision to establish a passageway from the exterior of the artery to the interior of the artery. The introducer passageway includes a valve to block blood flow out of the artery. One end of a guide wire is passed through the introducer into the vasculature. The wire is threaded through the vasculature until the inserted end reaches the treatment site. The opposing end of the guide wire extends outside the introducer. A collapsed stent is crimped onto a deflated balloon connected to one end of an elongated flexible tube, or catheter. The crimped stent is deployed by threading the balloon end of the catheter onto the exposed end of the guide wire, pushing the catheter through the introduces into the vessel and pushing the catheter along the wire until the balloon and stmt reach the treatment site. At the treatment site, the balloon is inflated causing the stent to radially expand and assume its second implantation diameter. The outer diameter of the expanded stent is greater than the inner diameter of the blood vessel at the treatment site, effectively causing an interference fit between the stent and the blood vessel that inhibits migration of the stmt. The balloon is deflated and withdrawn, along with the catheter and the wire. The introduces is then removed from the artery. ' Typical peripheral vascular applications for stents require a second expanded diameter in a range between about 4 millimeters to about 12 millimeters.
Introducers are sized according to a unit system whereby 1 French is the equivalent of one-thud of a millimeter. The introduces dimension referenced is the inner diameter of the introduces passageway. Therefore, a 9 French introduces is sized to receive an assembly for percutaneous deployment with a cross sectional profile no greater than 3 millimeters.
The introduces provides a passageway from the exterior environment into the vascular system. Reduction in the required size of the introduces results in a smaller entrance wound into the vascular system. A smaller entrance wound is desirable in order to minimize the necessity of surgically closing the incision once the introduces is removed. However, efforts to reduce the required size of the introduces are limited by the deployment cross sectional profile of the catheter, balloon and stent.
Typically the stent consists of two or more struts connected together into a radially collapsible and expandable frame. The struts define void areas upon expansion of the stent at the treatment site. Larger void areas can permit malignant tissue growth through the stmt spaces into the body passageway, and can also allow undesired contact between the blood and damaged portions of the interior surface of the vessel. Stent coverings have been proposed to alleviate the problems associated with void areas. Conventional stent coverings greatly increase the cross sectional profile of the catheter, balloon and stent, necessitating the use of larger introducers.
Larger introducers increase the risk that surgical closure of the entrance wound will be required and increase the risks associated with larger incisions.
- . CA 02206743 1997-06-03 One such covering consists of a sleeve having a predetermined outer diameter intended to be substantially the same as the inner diameter of the body passageway at the treatment site. For deployment, the sleeve is mechanically deformed around the collapsed stent by folding or bending the sleeve into a layered or bunched co~guration about the stent. The assembly of stent and sleeve is then crimped onto the balloon catheter and inserted through the introduces passageway into the vasculature and pushed to the treatment site.
The folded sleeve creates an uneven, bulky profile for the assembly that compromises easy insertion of the assembly through the introduces and prevents the use of an introduces having a reduced size. Further difficulties arise from the necessity of attaching the sleeve to the stent, by stitching, gluing or other time-consuming and labor intensive procedures.
The folded sleeve must also be maintained in the collapsed configuration during insertion and deployment. This is typically achieved by using a deployment 1 S sheath to constrain the folded sleeve. The sheath is then withdrawn at the treatment site, prior to inflation of the balloon. The sheath adds an additional dimension to the cross sectional profile of the assembly, further limiting the ability to restrict the size of the required introduces.
The deployment cross sectional profile of conventional covered stent assemblies capable of a second expanded diameter in a range between about 4 millimeters to about 12 millimeters requires the use of a 9 French introduces or larger. ' The size of the required introduces determines the size of the incision at the access site. Larger incisions increase the likelihood that surgical closure will be required.
Even if surgical closure is avoided, larger incisions increase the potential for developing hematomas and other bleeding complications.
The predetermined and fixed diameter of the conventional sleeve does not allow for any miscalculation in the required size. If the predetermined and fixed diameter is too small, the fully unfolded sleeve will block the assembly from engaging the interior surface of the passageway. If the fully unfolded sleeve is too large, the sleeve will bunch between the stent and the interior surface of the passageway.
Further, some porosity in the assembly may be desired, with pores of sufficient size to allow cellular ingrowth and capillary formation but small enough to prevent intrusions into the passageway as discussed above.
There remains a need for a covered stmt assembly with a covering that does not contribute significantly to the overall cross sectional profile of the assembly, allowing for the use of smaller introducers to reduce the risk that surgical closure of the entry wound will be required and to reduce the potential for bleeding complications. There is also a need for a covered stmt assembly with a covering that maintains its position relative to the stmt without the need for stitching, gluing or otherwise attaching the covering to the stmt. There is further a need for a covered stent assembly with a covering that does not require a precise prior determination of the second expanded diameter of the covering. ' Finally, there remains a need for a stent covering providing the above advantages that can be used with stents capable of a second expanded diameter in a range from about 4 millimeters to about 12 millimeters.
Summary of the Invention The present invention provides an endoprosthesis assembly for percutaneous deployment and implantation within a body passageway, comprising a radially expandable cylindrical frame and an elastomeric covering. The covering, or sleeve, avoids the problems associated with the void spaces of a bare stem, without contributing significantly to the cross sectional profile of the assembly.
Rather than assuming a fixed diameter prior to deployment, the elastomer sleeve assumes a first unexpanded diameter while the assembly is pushed through the introducer, and a second expanded diameter at the treatment site resulting from the expansion of the stent. The elastomeric sleeve is strong enough to withstand the stress associated with expansion of the stent to the second expanded diameter, and is compliant enough to avoid collapsing the stent after the expansion is complete. The deployment cross sectional profile of the assembly of the present invention allows a smaller introducer or other insertion device to be used than was previously possible using traditional coverings, minimizing the trauma at the introduction site and reducing the risk that surgical closure of the entry wound will be required.
Design features, such as porosity and wall thickness, as well as manufacturing techniques such as braiding, can be employed to increase the compliance of the - . CA 02206743 1997-06-03 S
expanded sleeve of the present invention and assure that the sleeve can be expanded within the required range without collapsing the expanded stent.
In accordance with the above, the present invention provides for an endoprosthesis assembly for percutaneous deployment and implantation within a body passageway, comprising a radially expandable cylindrical frame having first and second ends, a first unexpended outer diameter and a second expanded outer diameter.
The assembly further comprises a radially expandable elastomeric sleeve surrounding a length of the frame and having first and second ends, a first unexpended inner diameter and a second expanded inner diameter. A second expanded inner diameter of the sleeve is not greater than a second expanded outer diameter of the frame. A
second expanded inner diameter of the sleeve is in a range from about 60% to about 380% greater than a first unexpended inner diameter of the sleeve. The sleeve expands to a second expanded diameter without causing the expanded frame to collapse. In the preferred embodiment, a first unexpended inner diameter of the sleeve is not greater than a first unexpended outer diameter of the frame, so that at least a portion of the unexpended sleeve grips the unexpended frame prior to crimping onto the catheter.
In the preferred embodiment of the present invention, the expanded sleeve has a sleeve modulus in a range from about 100 psi to about 6000 psi, and a second expanded inner diameter in a range from about 4 millimeters to about 12 millimeters.
The frame hoop strength is about 30 psi at an expanded diameter of about 4 millimeters, and about 6 psi at an expanded diameter of about 12 millimeters.
The unexpended sleeve wall thickness is in a range from about .002 inches to about .005 inches, most preferably .005 inches.
The sleeve of the preferred embodiment comprises an elastomer having a percent elongation at break in a range from about S00 to about 585, an ultimate tensile strength in a range from about 4400 to about 5300 pounds per square inch, and a durometer hardness in a range from about 73 (shore A) to about 80 (shore A).
One such elastomer is a polycarbonate polyurethane. The assembly of the preferred embodiment is adapted to be disposed through an introducer having an inner diameter in a range from about 2.5 mm. to about 2.7 mm.
The compliance of the sleeve of the present invention can be adjusted by the use of various textile methods, such as braiding, lrnitting or weaving the sleeve from yarn spun from the elastomeric material. In the preferred embodiment, the sleeve is braided directly onto a frame that has assumed a first unexpended diameter.
The denier of the yarn is preferably in a range from about 10 to about 70, and is most preferably 40.
The present invention provides a method of percutaneously deploying an endoprosthesis assembly for implantation at a treatment site within a body passageway of a patient, comprising the steps of forming the assembly by surrounding a length of an unexpended cylindrical frame having a first unexpended outer diameter with an elastomeric sleeve having a first unexpended inner diameter, crimping the unexpended assembly onto a first end of an elongated flexible tube, or catheter, inserting the assembly inside the passageway, threading the catheter through the interior of the passageway until the first end of the catheter reaches the treatment site, expanding the frame to a second expanded outer diameter, and expanding the sleeve to a second expanded inner diameter not greater than a second expanded outer diameter of said frame and a second expanded outer diameter not less than the inner diameter of the body passageway.
These and other advantages and features of this invention will be clearly understood through consideration of the following detailed description of alternate embodiments of the invention in conjunction with the accompanying drawings.
Brief Description of the Drawings Figure 1 is a depiction of the unexpended assembly (enlarged) crimped onto a balloon attached to the end of a catheter. Figure 1 illustrates the catheter after one end has been threaded onto a guide wire and pushed through the introducer into the vasculature.
Figure 2 is a perspective depiction of the assembly, balloon, catheter and guide wire inside the introducer.
Figure 3 is a side view partially cut away and partially in section of the assembly, balloon, catheter and guide wire inside a blood vessel prior to inflation of the balloon.
Figure 4 is a side view partially cut away and partially in section of the assembly, balloon, catheter and guide wire inside a blood vessel after inflation of the balloon.
Figure 5 is a cross sectional view as seen approximately from the plane indicated by the line 5-5 of Figure 3.
Figure 6 is a cross sectional view as seen approximately from the plane indicated by the line 6-6 of Figure 4.
Figure 7 is a detail of a portion of Figure 5 as indicated therein, Figure 8 is a detail of a portion of Figure 6 as indicated therein.
Figure 9 is a schematic depiction of a machine for braiding a sleeve onto a stent to form the assembly.
Description of the Preferred Embodiment The present invention provides for an endoprosthesis assembly 10 for percutaneous deployment and implantation within a body passageway, comprising a radially expandable cylindrical frame 12 having first and second ends, a first unexpanded outer diameter and a second expanded outer diameter, The assembly further comprises a radially expandable elastomeric sleeve 14 surrounding a length of the frame 12. The sleeve 14 has first and second ends, a first unexpanded inner diameter and a second expanded inner diameter. The inner diameter of the expanded sleeve 14 is not greater than the outer diameter of the expanded frame. The second expanded inner diameter of said sleeve 14 is in a range from about 60% to about 38096 greater than said first unexpanded inner diameter of said sleeve.
The frame 12 has an open structure comprised of support members 16, or struts, joined to enable the frame to radially expand and collapse. The support members define void spaces 18 that expand as the frame expands. (Figures 3 and 4.) The support members 16 form a generally cylindrical shape with a longitudinal axis.
The frame 12 of the preferred embodiment comprises a stent manufactured from support members 16 consisting of tantalum wires having a diameter of .007 inches.
Such stents are known and disclosed, for example, in Pinchuk, U.S. Patent No.
AND METHOD OF DEPLOYING SAME
Field of the Invention This invention generally relates to an endoprosthesis assembly for percutaneous deployment and implantation into a blood vessel or other hollow body passageway, and a method for deploying an endoprosthesis assembly. More particularly, the invention relates to an assembly comprising a frame surrounded by an elastomeric sleeve, where the assembly has a reduced profile for percutaneous deployment.
Background of the Invention Various endoprostheses, or stems, have been proposed or developed for use in association with angioplasty treatments and other medical procedures wherein devices having expandable components are used to treat a condition within a body passageway such as a blood vessel. The stent is typically cylindrical or tubular in shape and has an open construction such as a scaffold, or frame. Stents are constructed so as to be radially collapsible. They are also radially expandable using techniques such as the introduction of a radially projecting force from inside the stent.
Stents for implantation into a blood vessel, artery or the like to maintain or restore the patency of the passageway have been deployed percutaneously to minimize the invasiveness associated with surgical exposure of the treatment site.
Percutaneous .
deployment is initiated by an incision into the vasculature of the patient, typically into ' the femoral artery. An introducer comprising a cylinder open at each end is disposed across the incision to establish a passageway from the exterior of the artery to the interior of the artery. The introducer passageway includes a valve to block blood flow out of the artery. One end of a guide wire is passed through the introducer into the vasculature. The wire is threaded through the vasculature until the inserted end reaches the treatment site. The opposing end of the guide wire extends outside the introducer. A collapsed stent is crimped onto a deflated balloon connected to one end of an elongated flexible tube, or catheter. The crimped stent is deployed by threading the balloon end of the catheter onto the exposed end of the guide wire, pushing the catheter through the introduces into the vessel and pushing the catheter along the wire until the balloon and stmt reach the treatment site. At the treatment site, the balloon is inflated causing the stent to radially expand and assume its second implantation diameter. The outer diameter of the expanded stent is greater than the inner diameter of the blood vessel at the treatment site, effectively causing an interference fit between the stent and the blood vessel that inhibits migration of the stmt. The balloon is deflated and withdrawn, along with the catheter and the wire. The introduces is then removed from the artery. ' Typical peripheral vascular applications for stents require a second expanded diameter in a range between about 4 millimeters to about 12 millimeters.
Introducers are sized according to a unit system whereby 1 French is the equivalent of one-thud of a millimeter. The introduces dimension referenced is the inner diameter of the introduces passageway. Therefore, a 9 French introduces is sized to receive an assembly for percutaneous deployment with a cross sectional profile no greater than 3 millimeters.
The introduces provides a passageway from the exterior environment into the vascular system. Reduction in the required size of the introduces results in a smaller entrance wound into the vascular system. A smaller entrance wound is desirable in order to minimize the necessity of surgically closing the incision once the introduces is removed. However, efforts to reduce the required size of the introduces are limited by the deployment cross sectional profile of the catheter, balloon and stent.
Typically the stent consists of two or more struts connected together into a radially collapsible and expandable frame. The struts define void areas upon expansion of the stent at the treatment site. Larger void areas can permit malignant tissue growth through the stmt spaces into the body passageway, and can also allow undesired contact between the blood and damaged portions of the interior surface of the vessel. Stent coverings have been proposed to alleviate the problems associated with void areas. Conventional stent coverings greatly increase the cross sectional profile of the catheter, balloon and stent, necessitating the use of larger introducers.
Larger introducers increase the risk that surgical closure of the entrance wound will be required and increase the risks associated with larger incisions.
- . CA 02206743 1997-06-03 One such covering consists of a sleeve having a predetermined outer diameter intended to be substantially the same as the inner diameter of the body passageway at the treatment site. For deployment, the sleeve is mechanically deformed around the collapsed stent by folding or bending the sleeve into a layered or bunched co~guration about the stent. The assembly of stent and sleeve is then crimped onto the balloon catheter and inserted through the introduces passageway into the vasculature and pushed to the treatment site.
The folded sleeve creates an uneven, bulky profile for the assembly that compromises easy insertion of the assembly through the introduces and prevents the use of an introduces having a reduced size. Further difficulties arise from the necessity of attaching the sleeve to the stent, by stitching, gluing or other time-consuming and labor intensive procedures.
The folded sleeve must also be maintained in the collapsed configuration during insertion and deployment. This is typically achieved by using a deployment 1 S sheath to constrain the folded sleeve. The sheath is then withdrawn at the treatment site, prior to inflation of the balloon. The sheath adds an additional dimension to the cross sectional profile of the assembly, further limiting the ability to restrict the size of the required introduces.
The deployment cross sectional profile of conventional covered stent assemblies capable of a second expanded diameter in a range between about 4 millimeters to about 12 millimeters requires the use of a 9 French introduces or larger. ' The size of the required introduces determines the size of the incision at the access site. Larger incisions increase the likelihood that surgical closure will be required.
Even if surgical closure is avoided, larger incisions increase the potential for developing hematomas and other bleeding complications.
The predetermined and fixed diameter of the conventional sleeve does not allow for any miscalculation in the required size. If the predetermined and fixed diameter is too small, the fully unfolded sleeve will block the assembly from engaging the interior surface of the passageway. If the fully unfolded sleeve is too large, the sleeve will bunch between the stent and the interior surface of the passageway.
Further, some porosity in the assembly may be desired, with pores of sufficient size to allow cellular ingrowth and capillary formation but small enough to prevent intrusions into the passageway as discussed above.
There remains a need for a covered stmt assembly with a covering that does not contribute significantly to the overall cross sectional profile of the assembly, allowing for the use of smaller introducers to reduce the risk that surgical closure of the entry wound will be required and to reduce the potential for bleeding complications. There is also a need for a covered stmt assembly with a covering that maintains its position relative to the stmt without the need for stitching, gluing or otherwise attaching the covering to the stmt. There is further a need for a covered stent assembly with a covering that does not require a precise prior determination of the second expanded diameter of the covering. ' Finally, there remains a need for a stent covering providing the above advantages that can be used with stents capable of a second expanded diameter in a range from about 4 millimeters to about 12 millimeters.
Summary of the Invention The present invention provides an endoprosthesis assembly for percutaneous deployment and implantation within a body passageway, comprising a radially expandable cylindrical frame and an elastomeric covering. The covering, or sleeve, avoids the problems associated with the void spaces of a bare stem, without contributing significantly to the cross sectional profile of the assembly.
Rather than assuming a fixed diameter prior to deployment, the elastomer sleeve assumes a first unexpanded diameter while the assembly is pushed through the introducer, and a second expanded diameter at the treatment site resulting from the expansion of the stent. The elastomeric sleeve is strong enough to withstand the stress associated with expansion of the stent to the second expanded diameter, and is compliant enough to avoid collapsing the stent after the expansion is complete. The deployment cross sectional profile of the assembly of the present invention allows a smaller introducer or other insertion device to be used than was previously possible using traditional coverings, minimizing the trauma at the introduction site and reducing the risk that surgical closure of the entry wound will be required.
Design features, such as porosity and wall thickness, as well as manufacturing techniques such as braiding, can be employed to increase the compliance of the - . CA 02206743 1997-06-03 S
expanded sleeve of the present invention and assure that the sleeve can be expanded within the required range without collapsing the expanded stent.
In accordance with the above, the present invention provides for an endoprosthesis assembly for percutaneous deployment and implantation within a body passageway, comprising a radially expandable cylindrical frame having first and second ends, a first unexpended outer diameter and a second expanded outer diameter.
The assembly further comprises a radially expandable elastomeric sleeve surrounding a length of the frame and having first and second ends, a first unexpended inner diameter and a second expanded inner diameter. A second expanded inner diameter of the sleeve is not greater than a second expanded outer diameter of the frame. A
second expanded inner diameter of the sleeve is in a range from about 60% to about 380% greater than a first unexpended inner diameter of the sleeve. The sleeve expands to a second expanded diameter without causing the expanded frame to collapse. In the preferred embodiment, a first unexpended inner diameter of the sleeve is not greater than a first unexpended outer diameter of the frame, so that at least a portion of the unexpended sleeve grips the unexpended frame prior to crimping onto the catheter.
In the preferred embodiment of the present invention, the expanded sleeve has a sleeve modulus in a range from about 100 psi to about 6000 psi, and a second expanded inner diameter in a range from about 4 millimeters to about 12 millimeters.
The frame hoop strength is about 30 psi at an expanded diameter of about 4 millimeters, and about 6 psi at an expanded diameter of about 12 millimeters.
The unexpended sleeve wall thickness is in a range from about .002 inches to about .005 inches, most preferably .005 inches.
The sleeve of the preferred embodiment comprises an elastomer having a percent elongation at break in a range from about S00 to about 585, an ultimate tensile strength in a range from about 4400 to about 5300 pounds per square inch, and a durometer hardness in a range from about 73 (shore A) to about 80 (shore A).
One such elastomer is a polycarbonate polyurethane. The assembly of the preferred embodiment is adapted to be disposed through an introducer having an inner diameter in a range from about 2.5 mm. to about 2.7 mm.
The compliance of the sleeve of the present invention can be adjusted by the use of various textile methods, such as braiding, lrnitting or weaving the sleeve from yarn spun from the elastomeric material. In the preferred embodiment, the sleeve is braided directly onto a frame that has assumed a first unexpended diameter.
The denier of the yarn is preferably in a range from about 10 to about 70, and is most preferably 40.
The present invention provides a method of percutaneously deploying an endoprosthesis assembly for implantation at a treatment site within a body passageway of a patient, comprising the steps of forming the assembly by surrounding a length of an unexpended cylindrical frame having a first unexpended outer diameter with an elastomeric sleeve having a first unexpended inner diameter, crimping the unexpended assembly onto a first end of an elongated flexible tube, or catheter, inserting the assembly inside the passageway, threading the catheter through the interior of the passageway until the first end of the catheter reaches the treatment site, expanding the frame to a second expanded outer diameter, and expanding the sleeve to a second expanded inner diameter not greater than a second expanded outer diameter of said frame and a second expanded outer diameter not less than the inner diameter of the body passageway.
These and other advantages and features of this invention will be clearly understood through consideration of the following detailed description of alternate embodiments of the invention in conjunction with the accompanying drawings.
Brief Description of the Drawings Figure 1 is a depiction of the unexpended assembly (enlarged) crimped onto a balloon attached to the end of a catheter. Figure 1 illustrates the catheter after one end has been threaded onto a guide wire and pushed through the introducer into the vasculature.
Figure 2 is a perspective depiction of the assembly, balloon, catheter and guide wire inside the introducer.
Figure 3 is a side view partially cut away and partially in section of the assembly, balloon, catheter and guide wire inside a blood vessel prior to inflation of the balloon.
Figure 4 is a side view partially cut away and partially in section of the assembly, balloon, catheter and guide wire inside a blood vessel after inflation of the balloon.
Figure 5 is a cross sectional view as seen approximately from the plane indicated by the line 5-5 of Figure 3.
Figure 6 is a cross sectional view as seen approximately from the plane indicated by the line 6-6 of Figure 4.
Figure 7 is a detail of a portion of Figure 5 as indicated therein, Figure 8 is a detail of a portion of Figure 6 as indicated therein.
Figure 9 is a schematic depiction of a machine for braiding a sleeve onto a stent to form the assembly.
Description of the Preferred Embodiment The present invention provides for an endoprosthesis assembly 10 for percutaneous deployment and implantation within a body passageway, comprising a radially expandable cylindrical frame 12 having first and second ends, a first unexpanded outer diameter and a second expanded outer diameter, The assembly further comprises a radially expandable elastomeric sleeve 14 surrounding a length of the frame 12. The sleeve 14 has first and second ends, a first unexpanded inner diameter and a second expanded inner diameter. The inner diameter of the expanded sleeve 14 is not greater than the outer diameter of the expanded frame. The second expanded inner diameter of said sleeve 14 is in a range from about 60% to about 38096 greater than said first unexpanded inner diameter of said sleeve.
The frame 12 has an open structure comprised of support members 16, or struts, joined to enable the frame to radially expand and collapse. The support members define void spaces 18 that expand as the frame expands. (Figures 3 and 4.) The support members 16 form a generally cylindrical shape with a longitudinal axis.
The frame 12 of the preferred embodiment comprises a stent manufactured from support members 16 consisting of tantalum wires having a diameter of .007 inches.
Such stents are known and disclosed, for example, in Pinchuk, U.S. Patent No.
5,019,090, ~ the preferred embodiment, expansion of the scent to the second expanded diameter is achieved ~ by inflation of a percutaneous transluminal angioplasty balloon 20 on which the stent 12 has been ciimped. It will be appreciated, however, that a stent expandable by alternate methods, such as self-expanding stents and thermally expanding stems, is within the scope of the present invention. In one preferred embodiment of the present invention, the assembly 10 can assume a first unexpended diameter of approximately 2 millimeters, and expand to a second diameter in a range from about 4 millimeters to about 7 millimeters. The stent 12 of this embodiment has a hoop strength ranging from about 30 pounds per square inch to about 18 pounds per square inch., respectively. Alternatively, the assembly 10 can be crimped to a first unexpended diameter of approximately 2.54 millimeters, and expanded to a second diameter in a range from about 8 millimeters to about 12 millimeters. The stent of this embodiment has a hoop strength ranging from about 18 pounds per square inch to about 6 pounds per square inch, respectively.
"Hoop strength" as used herein refers to the intraluminal force exerted by the expanded stent 12. This force is measured by expanding a stent within a latex tube (not shown). The pressure surrounding the exterior of the tube is gradually increased until the expanded stmt collapses. The pressure at collapse is denominated the "hoop strength" of the stent. It is generally appreciated by those skilled in the art that hoop strength is a function of the amount of expansion undergone by the stent.
Therefore, a stmt capable of expansion to a range of diameters has a corresponding range of hoop strengths. Typically, hoop strength and expanded stent diameter are inversely proportional.
The elastomeric sleeve 14 of the preferred embodiment concentrically surrounds a longitudinal extent of the stmt 12. The sleeve 14 has an inner surface 22 and an outer surface 24 that define a sleeve wall. As can best be seen from the detail depictions of the preferred embodiment in figures 7 and 8, the inner surface 22 of the unexpended sleeve engages the outer surface 26 of the unexpended stent 12.
(Figure 7.) The inner surface 22 of the expanded sleeve 14 engages the outer surface 26 of the expanded stent 12. (Figure 8.) The close hugging fit between the unexpended and expanded sleeve 14 and stent 12 of the preferred embodiment obviates the need for separate attachments to be formed between the sleeve and the stent and reduces the potential for separation of the sleeve 14 and stent 12 during deployment and implantation. ' It will be appreciated, however, that the unexpended sleeve and stent can be attached by tacking, sewing or other methods known in the art if play exists between the unexpanded sleeve and the unexpanded stent, without departing from the intended scope of the present invention. The thickness of the sleeve wall is reduced as the sleeve 14 expands, creating a larger opening within the vessel at the treatment site than would otherwise be available with conventional stent coverings having a fixed wall thickness.
The sleeve 14 of the present invention has an unexpanded wall thickness in a range from about .002 to about .005 inches, preferably about .005 inches. The assembly 10 of the preferred embodiment allows a 7.5 French introducer 28 to be used with an assembly 10 expandable to a maximum second diameter of about 7 mm, and an 8 French introducer 28 to be used with an assembly 10 expandable to a maximum second diameter of about 12 mm. Conventional assemblies comprising a stent and a covering require the use of a 9 French introducer in the first instance and a 12 French introducer in the second. This reduction in the required introducer size achieved by the present invention is of particular significance, since it reduces the risk that surgical closure of the entrance wound will be required. The reduction in the required introducer size also reduces the risk of developing hematomas and other bleeding complications.
It is of particular significance in the present invention that the sleeve 14 of the preferred embodiment can expand to greater than 380% of its unexpanded first diameter without causing the underlying stent 12 to collapse once expansion to the second expanded diameter is achieved by balloon inflation or otherwise. The "sleeve modulus" is an expression of the tendency of the expanded sleeve to collapse the expanded stent. As used herein, "sleeve modulus" is the stress experienced by the sleeve at a given expansion divided by the strain, or expansion of the sleeve.
In one aspect of the present invention, the range of sleeve modulii enabling the desired expansion without collapsing the expanded stent is believed to be related to the hoop strength of the expanded stent, the expanded diameter of the sleeve, the wall thickness of the sleeve at the expanded diameter, and the percent change in the sleeve diameter as follows:
sleeve modules - ~~l ~~P sucngth x sleeve I. D.
2 x sleeve wall thiclmess x % change sleeve drameter The sleeve modulus approximated using this expression is believed to be a maximum for the particular expanded stmt hoop strength, expanded sleeve wall thickness, expanded sleeve diameter and percent change in sleeve diameter.
Using the above relationship, it is believed the maximum sleeve modulus for a sleeve having an 5 unexpanded wall thickness of .005 inches covering a stent having a minimum hoop strength of 4 psi is approximately 100 psi for an expanded sleeve diameter from about 60% to about 380% greater than the unexpanded sleeve diameter. At the other end of the range, it is believed that the maximum sleeve modulus for a sleeve having an unexpanded wall thickness of .002 inches covering a stent having a minimum hoop 10 strength of 30 psi is approximately 6000 psi for an expanded sleeve diameter from about 60% to about 380% greater than the unexpanded sleeve diameter. It is believed that expanded sleeves having a sleeve modulus that exceeds the maximum sleeve modulus will cause the expanded stent to collapse.
The sleeve modulus range identified above facilitates the selection of a suitable elastomer material from which to manufacture the sleeve 14 of the present invention.
The sleeve modulus can be manipulated if needed to fall within the modulus range identified above by design options such as reducing the thickness of the sleeve wall, adding porosity to the sleeve, or using conventional textile fabrication techniques such as braiding, weaving or knitting to manipulate the stress associated with the expansion of the sleeve.
In the preferred embodiment, the sleeve 14 is manufactured from a polycarbonate polyurethane resin having known biodurable characteristics.
Other suitable elastomeric materials having a high elongation and a low modulus, such as silicones, can be used. In one aspect of the preferred embodiment the resin can be spun into a mufti-filament yarn and braided into a sleeve 14. In another aspect of the preferred embodiment, the resin can be extruded into a porous tube or a film used to form a sleeve 14 which is then slipped over a stent 12. The following examples are intended to be illustrative, and are not intended to limit the scope of the present invention.
The polycarbonate polyurethane resin is spun into a mufti-filament yarn. The yarn is braided into a sleeve. The properties of the polyurethane are identified:
elongation at break: 500%
ultimate tensile strength (psi): 4400 durometer hardness (shore A): 73 yarn denier: 40 S sleeve wall thickness, unexpended (in.): .005 A resin with the properties identified is available under the trademark Carbothane from Thermedics, Inc., 470 Wildwood St., Woburn, Massachusetts 01888-1799.
Figure 9 conceptually shows a braiding machine 52 that may be used to fabricate the sleeve 14. The sleeve 14 is braided directly onto the stent 12 as hereinafter described. The yarn 54 is wound onto eight bobbins 56 moving in a clockwise direction and eight bobbins 58 moving in a counter-clockwise direction.
The bobbins 56, 58 are fitted onto sixteen carriers (not shown) on the braiding machine 52. The braiding machine 52 has an opening 60 for a mandrel 62. The sixteen carriers move the bobbins 56, 58 around the mandrel 62 in two opposing directions, eight clockwise 56 and eight counter-clockwise 58. The stent 12 is crimped on the mandrel 62 and passed through the center of the sixteen revolving yarn carriers as the carriers rotate at a set speed causing the yarn 54 to braid onto the outer surface 26 of the unexpended stent 12. The braiding machine 52 provides several techniques to control the structure and properties of the braid, including the amount of tension in the yarn 54, the pitch of the braid, and the number of overbraids. After the braiding is completed the sleeve 14 may be annealed in an oven at 110' C
to relieve tension in the yarn 54, as well as to fuse overlapping yams 54 together.
In another aspect of the preferred embodiment, the braiding is performed directly on the mandrel 62. The braided sleeve 14 is slid off of the mandrel 62 and cut to the desired length. The sleeve 14 is slightly expanded and the unexpended stent 12 is placed within the slightly expanded sleeve 14. The sleeve 14 is then released allowing the sleeve 14 to contract or recoil onto the unexpended stent 12 to form the assembly 10. The assembly 10 is slightly further crimped to the deflated balloon 20 attached to the catheter 30 prior to percutaneous deployment.
The preferred yarn denier ranges from about 10 to about 70, with 40 the most preferred denier.
The polycarbonate polyurethane resin is extruded into a tube or film. The tube is cut into a sleeve. The film is cut into strips, and opposing ends are fused or otherwise joined into a cylindrical sleeve. The properties of the polyurethane are identified:
elongation at break: 585%
ultimate tensile strength (psi): 5300 durometer hardness (shore A): 80 film thickness, unexpended (in.): .002 tube wall thickness, unexpended (in.): .004 A resin with the properties identified is available under the trademark ChronoFlex available from Polymedica Biomaterials, Inc., 11 State Street, Woburn, Massachusetts 01801.
The extruded sleeve 14 is slid over an unexpended stent 12 to form the assembly 10. The assembly 10 is slightly further crimped to the deflated balloon 20 attached to the catheter 30 prior to percutaneous deployment.
A sleeve 14 manufactured from extruded film or tubing of the material described above requires the incorporation of porosity into the extruded material to create a sleeve 14 that will expand to about 380% of its first unexpended diameter without causing the expanded stent 12 to collapse. The addition of porosity reduces the sleeve modulus as discussed above. It will be appreciated that porosity can be ' incorporated into the extruded material without departing from the intended scope of the present invention. Porosity can be achieved by laser hole drilling after the extrusion is complete, or by the use of a polymer resin having particulate fillers that are later removed from the solid by chemical exposure or other techniques as are known in the art.
The assembly 10 during deployment is depicted in Figure 1. The assembly 10 has been crimped to the exterior of a deflated balloon 20. The first end region of a catheter 30 passes through the interior of the balloon 20 and is sealably connected thereto as is known. As depicted in Figure 1, the first end 38 of a guide wire 32 has been inserted through an introducer 28 and pushed through the vasculature to the treatment site, while the second end 40 of the guide wire 32 extends outside the introduces 28. The introduces 28 includes a hub 36 defining a passageway into the vasculature and preventing blood flow out of the vasculature. A hollow tube, or sheath 42 extends from the hub into a portion of the vasculature. The first end region of the catheter has been enlarged in Figure 1 to magnify the guide wire 32, catheter 30, balloon 20, stmt 12 and sleeve 14. Figure 2 illustrates the guide wire 32, catheter 30, deflated balloon 20, unexpanded stent 12 and sleeve 14 inside the introduces 28.
The length of the stmt 12 is less than the length of the balloon 20. As can best be seen in Figure 4, the stent 12 is positioned on the balloon 20 to avoid the ends of the balloon that taper to a sealed connection with the catheter 30 upon inflation.
The sleeve 14 of the preferred embodiment does not foreshorten upon expansion.
(Figures 3 and 4.) The cross sectional profile of the balloon 20, catheter 30, and crimped stent and sleeve 14 must be small enough to pass through the passageway provided by the introduces 28. (Figure 2.) An opening in the first end region of the catheter to a guide wire conduit within the catheter is threaded onto the guide wire second end 40.
The balloon 20, catheter 30, and unexpanded stmt 12 and sleeve 14 are pushed through the introduces hub 36 and along the guide wire 32 until the assembly reaches the treatment site. Figure 5 is a cross section of the assembly 10 at the treatment site prior to inflation of the balloon 20. The vessel 48 is partially occluded by the presence of plaque 50. Fluid is introduced into a fluid conduit 46 of the catheter 30 and expands the balloon 20, compressing the plaque 50. (Figure 6.) The inflated balloon 30 expands the stent 12 to a second diameter and the sleeve 14 to a second diameter. (Figures 4 and 6.) The fluid is then withdrawn, causing the balloon 20 to deflate. The catheter 30, balloon 20 and guide wire 32 are then withdrawn.
As can be seen in Figure 8, the expanded sleeve exterior surface 24 engages the interior surface of the plaque 50. The sleeve compliance enables the expanded sleeve 14 to conform around the struts 16 of the expanded stmt 12, creating an undulating outer surface of the assembly 10 implanted into the exposed surface of the plaque 50. This undulating outer surface of the expanded assembly increases the contact surface area between the obstructing tissue within the vessel and reduces the potential for migration of the assembly. While the preferred embodiment contemplates an assembly for deployment within the vasculature, it will be appreciated that the invention can be used to reinforce or restore the patency of other body passageways, such as the esophagus and trachea.
While the present invention has been described with a degree of particularity, it is the intent that the invention include all modifications and alterations from the S disclosed design falling within the spirit and scope of the appended claims.
"Hoop strength" as used herein refers to the intraluminal force exerted by the expanded stent 12. This force is measured by expanding a stent within a latex tube (not shown). The pressure surrounding the exterior of the tube is gradually increased until the expanded stmt collapses. The pressure at collapse is denominated the "hoop strength" of the stent. It is generally appreciated by those skilled in the art that hoop strength is a function of the amount of expansion undergone by the stent.
Therefore, a stmt capable of expansion to a range of diameters has a corresponding range of hoop strengths. Typically, hoop strength and expanded stent diameter are inversely proportional.
The elastomeric sleeve 14 of the preferred embodiment concentrically surrounds a longitudinal extent of the stmt 12. The sleeve 14 has an inner surface 22 and an outer surface 24 that define a sleeve wall. As can best be seen from the detail depictions of the preferred embodiment in figures 7 and 8, the inner surface 22 of the unexpended sleeve engages the outer surface 26 of the unexpended stent 12.
(Figure 7.) The inner surface 22 of the expanded sleeve 14 engages the outer surface 26 of the expanded stent 12. (Figure 8.) The close hugging fit between the unexpended and expanded sleeve 14 and stent 12 of the preferred embodiment obviates the need for separate attachments to be formed between the sleeve and the stent and reduces the potential for separation of the sleeve 14 and stent 12 during deployment and implantation. ' It will be appreciated, however, that the unexpended sleeve and stent can be attached by tacking, sewing or other methods known in the art if play exists between the unexpanded sleeve and the unexpanded stent, without departing from the intended scope of the present invention. The thickness of the sleeve wall is reduced as the sleeve 14 expands, creating a larger opening within the vessel at the treatment site than would otherwise be available with conventional stent coverings having a fixed wall thickness.
The sleeve 14 of the present invention has an unexpanded wall thickness in a range from about .002 to about .005 inches, preferably about .005 inches. The assembly 10 of the preferred embodiment allows a 7.5 French introducer 28 to be used with an assembly 10 expandable to a maximum second diameter of about 7 mm, and an 8 French introducer 28 to be used with an assembly 10 expandable to a maximum second diameter of about 12 mm. Conventional assemblies comprising a stent and a covering require the use of a 9 French introducer in the first instance and a 12 French introducer in the second. This reduction in the required introducer size achieved by the present invention is of particular significance, since it reduces the risk that surgical closure of the entrance wound will be required. The reduction in the required introducer size also reduces the risk of developing hematomas and other bleeding complications.
It is of particular significance in the present invention that the sleeve 14 of the preferred embodiment can expand to greater than 380% of its unexpanded first diameter without causing the underlying stent 12 to collapse once expansion to the second expanded diameter is achieved by balloon inflation or otherwise. The "sleeve modulus" is an expression of the tendency of the expanded sleeve to collapse the expanded stent. As used herein, "sleeve modulus" is the stress experienced by the sleeve at a given expansion divided by the strain, or expansion of the sleeve.
In one aspect of the present invention, the range of sleeve modulii enabling the desired expansion without collapsing the expanded stent is believed to be related to the hoop strength of the expanded stent, the expanded diameter of the sleeve, the wall thickness of the sleeve at the expanded diameter, and the percent change in the sleeve diameter as follows:
sleeve modules - ~~l ~~P sucngth x sleeve I. D.
2 x sleeve wall thiclmess x % change sleeve drameter The sleeve modulus approximated using this expression is believed to be a maximum for the particular expanded stmt hoop strength, expanded sleeve wall thickness, expanded sleeve diameter and percent change in sleeve diameter.
Using the above relationship, it is believed the maximum sleeve modulus for a sleeve having an 5 unexpanded wall thickness of .005 inches covering a stent having a minimum hoop strength of 4 psi is approximately 100 psi for an expanded sleeve diameter from about 60% to about 380% greater than the unexpanded sleeve diameter. At the other end of the range, it is believed that the maximum sleeve modulus for a sleeve having an unexpanded wall thickness of .002 inches covering a stent having a minimum hoop 10 strength of 30 psi is approximately 6000 psi for an expanded sleeve diameter from about 60% to about 380% greater than the unexpanded sleeve diameter. It is believed that expanded sleeves having a sleeve modulus that exceeds the maximum sleeve modulus will cause the expanded stent to collapse.
The sleeve modulus range identified above facilitates the selection of a suitable elastomer material from which to manufacture the sleeve 14 of the present invention.
The sleeve modulus can be manipulated if needed to fall within the modulus range identified above by design options such as reducing the thickness of the sleeve wall, adding porosity to the sleeve, or using conventional textile fabrication techniques such as braiding, weaving or knitting to manipulate the stress associated with the expansion of the sleeve.
In the preferred embodiment, the sleeve 14 is manufactured from a polycarbonate polyurethane resin having known biodurable characteristics.
Other suitable elastomeric materials having a high elongation and a low modulus, such as silicones, can be used. In one aspect of the preferred embodiment the resin can be spun into a mufti-filament yarn and braided into a sleeve 14. In another aspect of the preferred embodiment, the resin can be extruded into a porous tube or a film used to form a sleeve 14 which is then slipped over a stent 12. The following examples are intended to be illustrative, and are not intended to limit the scope of the present invention.
The polycarbonate polyurethane resin is spun into a mufti-filament yarn. The yarn is braided into a sleeve. The properties of the polyurethane are identified:
elongation at break: 500%
ultimate tensile strength (psi): 4400 durometer hardness (shore A): 73 yarn denier: 40 S sleeve wall thickness, unexpended (in.): .005 A resin with the properties identified is available under the trademark Carbothane from Thermedics, Inc., 470 Wildwood St., Woburn, Massachusetts 01888-1799.
Figure 9 conceptually shows a braiding machine 52 that may be used to fabricate the sleeve 14. The sleeve 14 is braided directly onto the stent 12 as hereinafter described. The yarn 54 is wound onto eight bobbins 56 moving in a clockwise direction and eight bobbins 58 moving in a counter-clockwise direction.
The bobbins 56, 58 are fitted onto sixteen carriers (not shown) on the braiding machine 52. The braiding machine 52 has an opening 60 for a mandrel 62. The sixteen carriers move the bobbins 56, 58 around the mandrel 62 in two opposing directions, eight clockwise 56 and eight counter-clockwise 58. The stent 12 is crimped on the mandrel 62 and passed through the center of the sixteen revolving yarn carriers as the carriers rotate at a set speed causing the yarn 54 to braid onto the outer surface 26 of the unexpended stent 12. The braiding machine 52 provides several techniques to control the structure and properties of the braid, including the amount of tension in the yarn 54, the pitch of the braid, and the number of overbraids. After the braiding is completed the sleeve 14 may be annealed in an oven at 110' C
to relieve tension in the yarn 54, as well as to fuse overlapping yams 54 together.
In another aspect of the preferred embodiment, the braiding is performed directly on the mandrel 62. The braided sleeve 14 is slid off of the mandrel 62 and cut to the desired length. The sleeve 14 is slightly expanded and the unexpended stent 12 is placed within the slightly expanded sleeve 14. The sleeve 14 is then released allowing the sleeve 14 to contract or recoil onto the unexpended stent 12 to form the assembly 10. The assembly 10 is slightly further crimped to the deflated balloon 20 attached to the catheter 30 prior to percutaneous deployment.
The preferred yarn denier ranges from about 10 to about 70, with 40 the most preferred denier.
The polycarbonate polyurethane resin is extruded into a tube or film. The tube is cut into a sleeve. The film is cut into strips, and opposing ends are fused or otherwise joined into a cylindrical sleeve. The properties of the polyurethane are identified:
elongation at break: 585%
ultimate tensile strength (psi): 5300 durometer hardness (shore A): 80 film thickness, unexpended (in.): .002 tube wall thickness, unexpended (in.): .004 A resin with the properties identified is available under the trademark ChronoFlex available from Polymedica Biomaterials, Inc., 11 State Street, Woburn, Massachusetts 01801.
The extruded sleeve 14 is slid over an unexpended stent 12 to form the assembly 10. The assembly 10 is slightly further crimped to the deflated balloon 20 attached to the catheter 30 prior to percutaneous deployment.
A sleeve 14 manufactured from extruded film or tubing of the material described above requires the incorporation of porosity into the extruded material to create a sleeve 14 that will expand to about 380% of its first unexpended diameter without causing the expanded stent 12 to collapse. The addition of porosity reduces the sleeve modulus as discussed above. It will be appreciated that porosity can be ' incorporated into the extruded material without departing from the intended scope of the present invention. Porosity can be achieved by laser hole drilling after the extrusion is complete, or by the use of a polymer resin having particulate fillers that are later removed from the solid by chemical exposure or other techniques as are known in the art.
The assembly 10 during deployment is depicted in Figure 1. The assembly 10 has been crimped to the exterior of a deflated balloon 20. The first end region of a catheter 30 passes through the interior of the balloon 20 and is sealably connected thereto as is known. As depicted in Figure 1, the first end 38 of a guide wire 32 has been inserted through an introducer 28 and pushed through the vasculature to the treatment site, while the second end 40 of the guide wire 32 extends outside the introduces 28. The introduces 28 includes a hub 36 defining a passageway into the vasculature and preventing blood flow out of the vasculature. A hollow tube, or sheath 42 extends from the hub into a portion of the vasculature. The first end region of the catheter has been enlarged in Figure 1 to magnify the guide wire 32, catheter 30, balloon 20, stmt 12 and sleeve 14. Figure 2 illustrates the guide wire 32, catheter 30, deflated balloon 20, unexpanded stent 12 and sleeve 14 inside the introduces 28.
The length of the stmt 12 is less than the length of the balloon 20. As can best be seen in Figure 4, the stent 12 is positioned on the balloon 20 to avoid the ends of the balloon that taper to a sealed connection with the catheter 30 upon inflation.
The sleeve 14 of the preferred embodiment does not foreshorten upon expansion.
(Figures 3 and 4.) The cross sectional profile of the balloon 20, catheter 30, and crimped stent and sleeve 14 must be small enough to pass through the passageway provided by the introduces 28. (Figure 2.) An opening in the first end region of the catheter to a guide wire conduit within the catheter is threaded onto the guide wire second end 40.
The balloon 20, catheter 30, and unexpanded stmt 12 and sleeve 14 are pushed through the introduces hub 36 and along the guide wire 32 until the assembly reaches the treatment site. Figure 5 is a cross section of the assembly 10 at the treatment site prior to inflation of the balloon 20. The vessel 48 is partially occluded by the presence of plaque 50. Fluid is introduced into a fluid conduit 46 of the catheter 30 and expands the balloon 20, compressing the plaque 50. (Figure 6.) The inflated balloon 30 expands the stent 12 to a second diameter and the sleeve 14 to a second diameter. (Figures 4 and 6.) The fluid is then withdrawn, causing the balloon 20 to deflate. The catheter 30, balloon 20 and guide wire 32 are then withdrawn.
As can be seen in Figure 8, the expanded sleeve exterior surface 24 engages the interior surface of the plaque 50. The sleeve compliance enables the expanded sleeve 14 to conform around the struts 16 of the expanded stmt 12, creating an undulating outer surface of the assembly 10 implanted into the exposed surface of the plaque 50. This undulating outer surface of the expanded assembly increases the contact surface area between the obstructing tissue within the vessel and reduces the potential for migration of the assembly. While the preferred embodiment contemplates an assembly for deployment within the vasculature, it will be appreciated that the invention can be used to reinforce or restore the patency of other body passageways, such as the esophagus and trachea.
While the present invention has been described with a degree of particularity, it is the intent that the invention include all modifications and alterations from the S disclosed design falling within the spirit and scope of the appended claims.
Claims (19)
1. An endoprosthesis assembly for percutaneous deployment and implantation within a body passageway, comprising:
a radially expandable cylindrical frame having first and second ends, said frame having a first unexpended outer diameter and a second expanded outer diameter;
a radially expandable elastomeric sleeve surrounding a length of said frame and having first and second ends, said sleeve having a first unexpended inner diameter and a second expanded inner diameter;
wherein said second expanded inner diameter of said sleeve is not greater than said second expanded outer diameter of said frame; and wherein said sleeve, when expanded, has a sleeve modulus in a range from about 100 psi to about 6000 psi; and wherein said second expanded inner diameter of said sleeve is in a range from about 60% to about 380% greater than said first unexpended inner diameter of said sleeve.
a radially expandable cylindrical frame having first and second ends, said frame having a first unexpended outer diameter and a second expanded outer diameter;
a radially expandable elastomeric sleeve surrounding a length of said frame and having first and second ends, said sleeve having a first unexpended inner diameter and a second expanded inner diameter;
wherein said second expanded inner diameter of said sleeve is not greater than said second expanded outer diameter of said frame; and wherein said sleeve, when expanded, has a sleeve modulus in a range from about 100 psi to about 6000 psi; and wherein said second expanded inner diameter of said sleeve is in a range from about 60% to about 380% greater than said first unexpended inner diameter of said sleeve.
2. The endoprosthesis assembly of claim 1, wherein said first unexpended inner diameter of said sleeve is not greater than said first unexpended outer diameter of said frame.
3. The endoprosthesis assembly of claim 1, wherein said second expanded inner diameter of said sleeve is in a range from about 4 mm to about 12 mm.
4. The endoprosthesis assembly of claim 1, wherein said sleeve comprises an elastomer having a percent elongation at break in a range from about 500 to about 585, an ultimate tensile strength in a range from about 4400 psi to about 5300 psi, and a durometer hardness in a range from about 73 (shore A) to about 80 (shore A).
5. The endoprosthesis assembly of claim 2, wherein said sleeve comprises an elastomer having a percent elongation at break in a range from about 500 to about 585, an ultimate tensile strength in a range from about 4400 psi to about 5300 psi, and a durometer hardness in a range from about 73 (shore A) to about 80 (shore A).
6. The endoprosthesis assembly of claim 3, wherein said sleeve comprises an elastomer having a percent elongation at break in a range from about 500 to about 585, an ultimate tensile strength in a range from about 4400 psi to about 5300 psi, and a durometer hardness in a range from about 73 (shore A) to about 80 (shore A).
7. The endoprosthesis assembly of claim 1, wherein said sleeve comprises a polycarbonate polyurethane.
8. The endoprosthesis assembly of claim 2, wherein said sleeve comprises a polycarbonate polyurethane.
9. The endoprosthesis assembly of claim 3, wherein said sleeve comprises a polycarbonate polyurethane.
10. The endoprosthesis assembly of claim 1, wherein said assembly is adapted to be disposed through an introducer having an inner diameter in a range from about 2.5 mm to about 2.7 mm.
11. The endoprosthesis assembly of claim 10, wherein said second expanded inner diameter of said sleeve is in a range from about 4 mm to about 7 mm.
12. The endoprosthesis assembly of claim 10, wherein said second expanded inner diameter of said sleeve is in a range from about 7 mm to about 12 mm.
13. The endoprosthesis assembly of claim 1, wherein said sleeve is braided from yarn spun from said elastomeric material.
14. The endoprosthesis assembly of claim 1, wherein said sleeve is knitted from yarn spun from said elastomeric material.
15. The endoprosthesis assembly of claim 1, wherein said sleeve is woven from yarn spun from said elastomeric material.
16. The endoprosthesis assembly of claim 13, wherein said yarn has a denier in a range from about 10 to about 70.
17. The endoprosthesis assembly of claim 14, wherein said yarn has a denier in a range from about 10 to about 70.
18. The endoprosthesis assembly of claim 15, wherein said yarn has a denier in a range from about 10 to about 70.
19. The endoprosthesis assembly of claim 1, wherein said sleeve, when unexpanded, has a wall thickness in a range from about 0.002 inches to about 0.005 inches and wherein said frame has a hoop strength in a range from about psi to about 30 psi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/668,345 US5843161A (en) | 1996-06-26 | 1996-06-26 | Endoprosthesis assembly for percutaneous deployment and method of deploying same |
US08/668,345 | 1996-06-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2206743A1 CA2206743A1 (en) | 1997-12-26 |
CA2206743C true CA2206743C (en) | 2007-04-03 |
Family
ID=24681970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002206743A Expired - Lifetime CA2206743C (en) | 1996-06-26 | 1997-06-03 | Endoprosthesis assembly for percutaneous deployment and method of deploying same |
Country Status (4)
Country | Link |
---|---|
US (1) | US5843161A (en) |
EP (1) | EP0815805B1 (en) |
CA (1) | CA2206743C (en) |
DE (1) | DE69738006T2 (en) |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2089131C1 (en) * | 1993-12-28 | 1997-09-10 | Сергей Апполонович Пульнев | Stent-expander |
US6579314B1 (en) | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
US6451047B2 (en) | 1995-03-10 | 2002-09-17 | Impra, Inc. | Encapsulated intraluminal stent-graft and methods of making same |
US6264684B1 (en) | 1995-03-10 | 2001-07-24 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Helically supported graft |
US5957974A (en) * | 1997-01-23 | 1999-09-28 | Schneider (Usa) Inc | Stent graft with braided polymeric sleeve |
DE19703482A1 (en) * | 1997-01-31 | 1998-08-06 | Ernst Peter Prof Dr M Strecker | Stent |
WO1999042156A1 (en) | 1998-02-24 | 1999-08-26 | Boston Scientific Limited | High flow rate dialysis catheters and related methods |
US6482217B1 (en) | 1998-04-10 | 2002-11-19 | Endicor Medical, Inc. | Neuro thrombectomy catheter |
US6001112A (en) | 1998-04-10 | 1999-12-14 | Endicor Medical, Inc. | Rotational atherectomy device |
US6666874B2 (en) | 1998-04-10 | 2003-12-23 | Endicor Medical, Inc. | Rotational atherectomy system with serrated cutting tip |
US7815763B2 (en) | 2001-09-28 | 2010-10-19 | Abbott Laboratories Vascular Enterprises Limited | Porous membranes for medical implants and methods of manufacture |
US7887578B2 (en) | 1998-09-05 | 2011-02-15 | Abbott Laboratories Vascular Enterprises Limited | Stent having an expandable web structure |
US6682554B2 (en) | 1998-09-05 | 2004-01-27 | Jomed Gmbh | Methods and apparatus for a stent having an expandable web structure |
US20020019660A1 (en) * | 1998-09-05 | 2002-02-14 | Marc Gianotti | Methods and apparatus for a curved stent |
US6755856B2 (en) | 1998-09-05 | 2004-06-29 | Abbott Laboratories Vascular Enterprises Limited | Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
US6398803B1 (en) | 1999-02-02 | 2002-06-04 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Partial encapsulation of stents |
US6558414B2 (en) | 1999-02-02 | 2003-05-06 | Impra, Inc. | Partial encapsulation of stents using strips and bands |
US7708749B2 (en) | 2000-12-20 | 2010-05-04 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US8328829B2 (en) | 1999-08-19 | 2012-12-11 | Covidien Lp | High capacity debulking catheter with razor edge cutting window |
US7713279B2 (en) | 2000-12-20 | 2010-05-11 | Fox Hollow Technologies, Inc. | Method and devices for cutting tissue |
US6299622B1 (en) | 1999-08-19 | 2001-10-09 | Fox Hollow Technologies, Inc. | Atherectomy catheter with aligned imager |
US6533806B1 (en) * | 1999-10-01 | 2003-03-18 | Scimed Life Systems, Inc. | Balloon yielded delivery system and endovascular graft design for easy deployment |
US6264671B1 (en) | 1999-11-15 | 2001-07-24 | Advanced Cardiovascular Systems, Inc. | Stent delivery catheter and method of use |
US7278195B2 (en) * | 1999-12-16 | 2007-10-09 | Israel Aircraft Industries Ltd. | Method for producing a coated medical support device |
US6585759B1 (en) | 1999-12-16 | 2003-07-01 | Israel Aircraft Industries Ltd. | Method and apparatus for manufacturing medical support devices |
JP2004506469A (en) | 2000-08-18 | 2004-03-04 | アトリテック, インコーポレイテッド | Expandable implantable device for filtering blood flow from the atrial appendage |
AU2001286731A1 (en) * | 2000-08-25 | 2002-03-04 | Kensey Nash Corporation | Covered stents, systems for deploying covered stents |
WO2002024247A1 (en) | 2000-09-22 | 2002-03-28 | Kensey Nash Corporation | Drug delivering prostheses and methods of use |
US6770086B1 (en) | 2000-11-02 | 2004-08-03 | Scimed Life Systems, Inc. | Stent covering formed of porous polytetraflouroethylene |
US6900197B2 (en) * | 2000-12-15 | 2005-05-31 | Mitokor | Cobalt-porphyrin complexes and use thereof as an anti-obesity agent |
EP2353526B1 (en) | 2000-12-20 | 2013-09-04 | Covidien LP | Catheter for removing atheromatous or thrombotic occlusive material |
US6641607B1 (en) | 2000-12-29 | 2003-11-04 | Advanced Cardiovascular Systems, Inc. | Double tube stent |
US6699274B2 (en) * | 2001-01-22 | 2004-03-02 | Scimed Life Systems, Inc. | Stent delivery system and method of manufacturing same |
US7717708B2 (en) * | 2001-04-13 | 2010-05-18 | Orametrix, Inc. | Method and system for integrated orthodontic treatment planning using unified workstation |
US7828833B2 (en) | 2001-06-11 | 2010-11-09 | Boston Scientific Scimed, Inc. | Composite ePTFE/textile prosthesis |
ATE303170T1 (en) * | 2001-06-11 | 2005-09-15 | Boston Scient Ltd | COMPOSITE EPTFE/TEXTIL PROSTHESIS |
US7560006B2 (en) * | 2001-06-11 | 2009-07-14 | Boston Scientific Scimed, Inc. | Pressure lamination method for forming composite ePTFE/textile and ePTFE/stent/textile prostheses |
US8591782B2 (en) * | 2002-08-23 | 2013-11-26 | National Cerebral And Cardiovascular Center | Process for producing stent |
JP5445649B2 (en) * | 2002-08-23 | 2014-03-19 | 独立行政法人国立循環器病研究センター | Stent |
US7655021B2 (en) * | 2003-03-10 | 2010-02-02 | Boston Scientific Scimed, Inc. | Dilator with expandable member |
US8246640B2 (en) | 2003-04-22 | 2012-08-21 | Tyco Healthcare Group Lp | Methods and devices for cutting tissue at a vascular location |
EP1653888B1 (en) * | 2003-07-21 | 2009-09-09 | The Trustees of The University of Pennsylvania | Percutaneous heart valve |
US20120041550A1 (en) | 2003-12-23 | 2012-02-16 | Sadra Medical, Inc. | Methods and Apparatus for Endovascular Heart Valve Replacement Comprising Tissue Grasping Elements |
US11278398B2 (en) | 2003-12-23 | 2022-03-22 | Boston Scientific Scimed, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
US8828078B2 (en) | 2003-12-23 | 2014-09-09 | Sadra Medical, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
US8343213B2 (en) | 2003-12-23 | 2013-01-01 | Sadra Medical, Inc. | Leaflet engagement elements and methods for use thereof |
US8840663B2 (en) | 2003-12-23 | 2014-09-23 | Sadra Medical, Inc. | Repositionable heart valve method |
US7381219B2 (en) | 2003-12-23 | 2008-06-03 | Sadra Medical, Inc. | Low profile heart valve and delivery system |
US8377110B2 (en) * | 2004-04-08 | 2013-02-19 | Endologix, Inc. | Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve |
CA2570142A1 (en) * | 2004-07-07 | 2006-02-09 | Cook Incorporated | Graft, stent graft and method for manufacture |
WO2006010130A1 (en) * | 2004-07-09 | 2006-01-26 | University Of Florida Research Foundation, Inc. | Tubular polymer stent coverings |
US7892592B1 (en) * | 2004-11-30 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Coating abluminal surfaces of stents and other implantable medical devices |
US9545300B2 (en) | 2004-12-22 | 2017-01-17 | W. L. Gore & Associates, Inc. | Filament-wound implantable devices |
DE102005003632A1 (en) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Catheter for the transvascular implantation of heart valve prostheses |
CA2843097C (en) | 2005-05-24 | 2015-10-27 | Inspire M.D Ltd. | Stent apparatuses for treatment via body lumens and methods of use |
US8043323B2 (en) | 2006-10-18 | 2011-10-25 | Inspiremd Ltd. | In vivo filter assembly |
US8961586B2 (en) * | 2005-05-24 | 2015-02-24 | Inspiremd Ltd. | Bifurcated stent assemblies |
US7569071B2 (en) | 2005-09-21 | 2009-08-04 | Boston Scientific Scimed, Inc. | Venous valve, system, and method with sinus pocket |
US8764820B2 (en) | 2005-11-16 | 2014-07-01 | Edwards Lifesciences Corporation | Transapical heart valve delivery system and method |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
CN101415379B (en) | 2006-02-14 | 2012-06-20 | 萨德拉医学公司 | Systems for delivering a medical implant |
US20070276419A1 (en) | 2006-05-26 | 2007-11-29 | Fox Hollow Technologies, Inc. | Methods and devices for rotating an active element and an energy emitter on a catheter |
EP2043570B1 (en) | 2006-07-10 | 2018-10-31 | First Quality Hygienic, Inc. | Resilient device |
US10004584B2 (en) | 2006-07-10 | 2018-06-26 | First Quality Hygienic, Inc. | Resilient intravaginal device |
US8613698B2 (en) | 2006-07-10 | 2013-12-24 | Mcneil-Ppc, Inc. | Resilient device |
US7717892B2 (en) | 2006-07-10 | 2010-05-18 | Mcneil-Ppc, Inc. | Method of treating urinary incontinence |
US10219884B2 (en) | 2006-07-10 | 2019-03-05 | First Quality Hygienic, Inc. | Resilient device |
US20080125752A1 (en) * | 2006-08-09 | 2008-05-29 | Boston Scientific Scimed, Inc. | Catheter assembly having a modified reinforcement layer |
US20080051759A1 (en) * | 2006-08-24 | 2008-02-28 | Boston Scientific Scimed, Inc. | Polycarbonate polyurethane venous access devices |
US20100204772A1 (en) * | 2006-10-18 | 2010-08-12 | Asher Holzer | Filter Assemblies |
EP2076212B1 (en) * | 2006-10-18 | 2017-03-29 | Inspiremd Ltd. | Knitted stent jackets |
US20100324664A1 (en) * | 2006-10-18 | 2010-12-23 | Asher Holzer | Bifurcated Stent Assemblies |
US9622888B2 (en) | 2006-11-16 | 2017-04-18 | W. L. Gore & Associates, Inc. | Stent having flexibly connected adjacent stent elements |
CA3013758C (en) | 2006-11-22 | 2021-09-14 | Inspiremd Ltd. | Intravascular aneurysm treatment device and methods |
US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
US8128679B2 (en) | 2007-05-23 | 2012-03-06 | Abbott Laboratories Vascular Enterprises Limited | Flexible stent with torque-absorbing connectors |
US8016874B2 (en) | 2007-05-23 | 2011-09-13 | Abbott Laboratories Vascular Enterprises Limited | Flexible stent with elevated scaffolding properties |
JP5628673B2 (en) | 2007-09-26 | 2014-11-19 | セント ジュード メディカル インコーポレイテッド | Foldable prosthetic heart valve |
US9532868B2 (en) | 2007-09-28 | 2017-01-03 | St. Jude Medical, Inc. | Collapsible-expandable prosthetic heart valves with structures for clamping native tissue |
WO2009052506A1 (en) * | 2007-10-19 | 2009-04-23 | Navilyst Medical, Inc. | Recirculation minimizing catheter |
US7850726B2 (en) | 2007-12-20 | 2010-12-14 | Abbott Laboratories Vascular Enterprises Limited | Endoprosthesis having struts linked by foot extensions |
US8920488B2 (en) | 2007-12-20 | 2014-12-30 | Abbott Laboratories Vascular Enterprises Limited | Endoprosthesis having a stable architecture |
US8337544B2 (en) | 2007-12-20 | 2012-12-25 | Abbott Laboratories Vascular Enterprises Limited | Endoprosthesis having flexible connectors |
US8926688B2 (en) | 2008-01-11 | 2015-01-06 | W. L. Gore & Assoc. Inc. | Stent having adjacent elements connected by flexible webs |
US8784440B2 (en) | 2008-02-25 | 2014-07-22 | Covidien Lp | Methods and devices for cutting tissue |
US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
WO2011104269A1 (en) | 2008-02-26 | 2011-09-01 | Jenavalve Technology Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US8196279B2 (en) | 2008-02-27 | 2012-06-12 | C. R. Bard, Inc. | Stent-graft covering process |
EP3025681B1 (en) | 2008-07-15 | 2017-02-01 | St. Jude Medical, Inc. | Collabsible and re-expandable prosthetic heart valve cuff designs and complementary technological applications |
JP5607639B2 (en) | 2008-10-10 | 2014-10-15 | サドラ メディカル インコーポレイテッド | Medical devices and systems |
KR101645754B1 (en) | 2008-10-13 | 2016-08-04 | 코비디엔 엘피 | Devices and methods for manipulating a catheter shaft |
BRPI1014721A2 (en) | 2009-04-29 | 2016-04-12 | Tyco Healthcare | methods and devices for cutting and scraping fabric |
CA2761774C (en) | 2009-05-14 | 2014-09-16 | Tyco Healthcare Group Lp | Easily cleaned atherectomy catheters and methods of use |
GB0909319D0 (en) * | 2009-05-29 | 2009-07-15 | Angiomed Ag | Transluminal delivery system |
US8439970B2 (en) | 2009-07-14 | 2013-05-14 | Edwards Lifesciences Corporation | Transapical delivery system for heart valves |
BR112012013389A2 (en) | 2009-12-02 | 2018-03-06 | Tyco Healthcare | methods and devices for cutting a fabric |
CA2783301C (en) | 2009-12-11 | 2015-02-24 | Tyco Healthcare Group Lp | Material removal device having improved material capture efficiency and methods of use |
US8328760B2 (en) | 2010-01-11 | 2012-12-11 | Angiodynamics, Inc. | Occlusion resistant catheter |
CN103002833B (en) | 2010-05-25 | 2016-05-11 | 耶拿阀门科技公司 | Artificial heart valve and comprise artificial heart valve and support through conduit carry interior prosthese |
EP2742881B1 (en) | 2010-06-14 | 2015-10-07 | Covidien LP | Material removal device |
CA2808673C (en) | 2010-09-10 | 2019-07-02 | Symetis Sa | Valve replacement devices, delivery device for a valve replacement device and method of production of a valve replacement device |
PT3626208T (en) | 2010-10-05 | 2021-04-22 | Edwards Lifesciences Corp | Prosthetic heart valve |
JP5636114B2 (en) | 2010-10-28 | 2014-12-03 | コヴィディエン リミテッド パートナーシップ | Substance removal device and method of use |
CN103281964B (en) | 2010-11-11 | 2015-09-30 | 科维蒂恩有限合伙公司 | The flexibility possessing imaging capability subtracts the method for go out conduit and manufacture conduit |
US9226824B2 (en) | 2010-11-30 | 2016-01-05 | Edwards Lifesciences Corporation | Surgical stabilizer and closure system |
US10166128B2 (en) | 2011-01-14 | 2019-01-01 | W. L. Gore & Associates. Inc. | Lattice |
US9839540B2 (en) | 2011-01-14 | 2017-12-12 | W. L. Gore & Associates, Inc. | Stent |
US9999746B2 (en) | 2011-03-22 | 2018-06-19 | Angiodynamics, Inc. | High flow catheters |
US9050435B2 (en) | 2011-03-22 | 2015-06-09 | Angiodynamics, Inc. | High flow catheters |
US9744033B2 (en) | 2011-04-01 | 2017-08-29 | W.L. Gore & Associates, Inc. | Elastomeric leaflet for prosthetic heart valves |
US9055937B2 (en) | 2011-04-01 | 2015-06-16 | Edwards Lifesciences Corporation | Apical puncture access and closure system |
US9381082B2 (en) | 2011-04-22 | 2016-07-05 | Edwards Lifesciences Corporation | Devices, systems and methods for accurate positioning of a prosthetic valve |
EP2520251A1 (en) | 2011-05-05 | 2012-11-07 | Symetis SA | Method and Apparatus for Compressing Stent-Valves |
WO2013013032A2 (en) | 2011-07-20 | 2013-01-24 | Boston Scientific Scimed, Inc. | Heart valve replacement |
CN104039271B (en) | 2011-07-29 | 2016-09-07 | 卡内基梅隆大学 | Artificial valve conduit and production method thereof for cardiac reconstruction operation |
WO2013033426A2 (en) | 2011-09-01 | 2013-03-07 | Covidien Lp | Catheter with helical drive shaft and methods of manufacture |
US9554806B2 (en) | 2011-09-16 | 2017-01-31 | W. L. Gore & Associates, Inc. | Occlusive devices |
US9510935B2 (en) | 2012-01-16 | 2016-12-06 | W. L. Gore & Associates, Inc. | Articles including expanded polytetrafluoroethylene membranes with serpentine fibrils and having a discontinuous fluoropolymer layer thereon |
US9883941B2 (en) | 2012-06-19 | 2018-02-06 | Boston Scientific Scimed, Inc. | Replacement heart valve |
US9283072B2 (en) | 2012-07-25 | 2016-03-15 | W. L. Gore & Associates, Inc. | Everting transcatheter valve and methods |
US9579157B2 (en) | 2012-09-13 | 2017-02-28 | Covidien Lp | Cleaning device for medical instrument and method of use |
US9943329B2 (en) | 2012-11-08 | 2018-04-17 | Covidien Lp | Tissue-removing catheter with rotatable cutter |
WO2014074764A1 (en) | 2012-11-08 | 2014-05-15 | Covidien Lp | Tissue-removing catheter including operational control mechanism |
US9931193B2 (en) | 2012-11-13 | 2018-04-03 | W. L. Gore & Associates, Inc. | Elastic stent graft |
US10279084B2 (en) | 2012-12-19 | 2019-05-07 | W. L. Gore & Associates, Inc. | Medical balloon devices and methods |
US9968443B2 (en) | 2012-12-19 | 2018-05-15 | W. L. Gore & Associates, Inc. | Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet |
US9144492B2 (en) | 2012-12-19 | 2015-09-29 | W. L. Gore & Associates, Inc. | Truncated leaflet for prosthetic heart valves, preformed valve |
US9101469B2 (en) | 2012-12-19 | 2015-08-11 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with leaflet shelving |
AU2014225445B2 (en) * | 2013-03-08 | 2018-09-20 | Carnegie Mellon University | Expandable implantable conduit |
US10149757B2 (en) | 2013-03-15 | 2018-12-11 | Edwards Lifesciences Corporation | System and method for transaortic delivery of a prosthetic heart valve |
US11911258B2 (en) | 2013-06-26 | 2024-02-27 | W. L. Gore & Associates, Inc. | Space filling devices |
JP6563394B2 (en) | 2013-08-30 | 2019-08-21 | イェーナヴァルヴ テクノロジー インコーポレイテッド | Radially foldable frame for an artificial valve and method for manufacturing the frame |
US9913715B2 (en) | 2013-11-06 | 2018-03-13 | St. Jude Medical, Cardiology Division, Inc. | Paravalvular leak sealing mechanism |
US10842918B2 (en) | 2013-12-05 | 2020-11-24 | W.L. Gore & Associates, Inc. | Length extensible implantable device and methods for making such devices |
US9456843B2 (en) | 2014-02-03 | 2016-10-04 | Covidien Lp | Tissue-removing catheter including angular displacement sensor |
US9526519B2 (en) | 2014-02-03 | 2016-12-27 | Covidien Lp | Tissue-removing catheter with improved angular tissue-removing positioning within body lumen |
US10154904B2 (en) | 2014-04-28 | 2018-12-18 | Edwards Lifesciences Corporation | Intravascular introducer devices |
US10195025B2 (en) | 2014-05-12 | 2019-02-05 | Edwards Lifesciences Corporation | Prosthetic heart valve |
EP3134033B1 (en) | 2014-05-29 | 2018-04-04 | Edwards Lifesciences CardiAQ LLC | Prosthesis and delivery device |
WO2015200702A1 (en) | 2014-06-27 | 2015-12-30 | Covidien Lp | Cleaning device for catheter and catheter including the same |
US9827094B2 (en) | 2014-09-15 | 2017-11-28 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with retention elements |
US10299948B2 (en) | 2014-11-26 | 2019-05-28 | W. L. Gore & Associates, Inc. | Balloon expandable endoprosthesis |
WO2016126524A1 (en) | 2015-02-03 | 2016-08-11 | Boston Scientific Scimed, Inc. | Prosthetic heart valve having tubular seal |
US10426617B2 (en) | 2015-03-06 | 2019-10-01 | Boston Scientific Scimed, Inc. | Low profile valve locking mechanism and commissure assembly |
US10314667B2 (en) | 2015-03-25 | 2019-06-11 | Covidien Lp | Cleaning device for cleaning medical instrument |
US10232564B2 (en) | 2015-04-29 | 2019-03-19 | Edwards Lifesciences Corporation | Laminated sealing member for prosthetic heart valve |
CN107530168B (en) | 2015-05-01 | 2020-06-09 | 耶拿阀门科技股份有限公司 | Device and method with reduced pacemaker ratio in heart valve replacement |
ES2908460T3 (en) | 2015-05-14 | 2022-04-29 | Gore & Ass | Devices for occlusion of an atrial appendage |
US9974650B2 (en) | 2015-07-14 | 2018-05-22 | Edwards Lifesciences Corporation | Prosthetic heart valve |
US10292721B2 (en) | 2015-07-20 | 2019-05-21 | Covidien Lp | Tissue-removing catheter including movable distal tip |
US10631977B2 (en) | 2015-08-24 | 2020-04-28 | Edwards Lifesciences Corporation | Covering and assembly method for transcatheter valve |
US10314664B2 (en) | 2015-10-07 | 2019-06-11 | Covidien Lp | Tissue-removing catheter and tissue-removing element with depth stop |
US10179043B2 (en) | 2016-02-12 | 2019-01-15 | Edwards Lifesciences Corporation | Prosthetic heart valve having multi-level sealing member |
WO2017151900A1 (en) | 2016-03-02 | 2017-09-08 | Peca Labs, Inc. | Expandable implantable conduit |
ES2956016T3 (en) | 2016-04-21 | 2023-12-11 | Gore & Ass | Diametrically adjustable endoprostheses |
EP4183371A1 (en) | 2016-05-13 | 2023-05-24 | JenaValve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system |
US10201416B2 (en) | 2016-05-16 | 2019-02-12 | Boston Scientific Scimed, Inc. | Replacement heart valve implant with invertible leaflets |
US10568752B2 (en) | 2016-05-25 | 2020-02-25 | W. L. Gore & Associates, Inc. | Controlled endoprosthesis balloon expansion |
WO2018071417A1 (en) | 2016-10-10 | 2018-04-19 | Peca Labs, Inc. | Transcatheter stent and valve assembly |
US10813749B2 (en) | 2016-12-20 | 2020-10-27 | Edwards Lifesciences Corporation | Docking device made with 3D woven fabric |
JP7094965B2 (en) | 2017-01-27 | 2022-07-04 | イエナバルブ テクノロジー インク | Heart valve imitation |
WO2018226915A1 (en) | 2017-06-08 | 2018-12-13 | Boston Scientific Scimed, Inc. | Heart valve implant commissure support structure |
CN111163729B (en) | 2017-08-01 | 2022-03-29 | 波士顿科学国际有限公司 | Medical implant locking mechanism |
US10939996B2 (en) | 2017-08-16 | 2021-03-09 | Boston Scientific Scimed, Inc. | Replacement heart valve commissure assembly |
AU2018342222B2 (en) | 2017-09-27 | 2021-05-20 | Edwards Lifesciences Corporation | Prosthetic valve with expandable frame and associated systems and methods |
US11173023B2 (en) | 2017-10-16 | 2021-11-16 | W. L. Gore & Associates, Inc. | Medical devices and anchors therefor |
US11439502B2 (en) | 2017-10-31 | 2022-09-13 | W. L. Gore & Associates, Inc. | Medical valve and leaflet promoting tissue ingrowth |
JP7055882B2 (en) | 2018-01-19 | 2022-04-18 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Guidance mode indwelling sensor for transcatheter valve system |
US11246625B2 (en) | 2018-01-19 | 2022-02-15 | Boston Scientific Scimed, Inc. | Medical device delivery system with feedback loop |
US11147668B2 (en) | 2018-02-07 | 2021-10-19 | Boston Scientific Scimed, Inc. | Medical device delivery system with alignment feature |
WO2019165394A1 (en) | 2018-02-26 | 2019-08-29 | Boston Scientific Scimed, Inc. | Embedded radiopaque marker in adaptive seal |
CN112399836A (en) | 2018-05-15 | 2021-02-23 | 波士顿科学国际有限公司 | Replacement heart valve commissure assemblies |
US11241310B2 (en) | 2018-06-13 | 2022-02-08 | Boston Scientific Scimed, Inc. | Replacement heart valve delivery device |
WO2020123486A1 (en) | 2018-12-10 | 2020-06-18 | Boston Scientific Scimed, Inc. | Medical device delivery system including a resistance member |
US11497601B2 (en) | 2019-03-01 | 2022-11-15 | W. L. Gore & Associates, Inc. | Telescoping prosthetic valve with retention element |
US11439504B2 (en) | 2019-05-10 | 2022-09-13 | Boston Scientific Scimed, Inc. | Replacement heart valve with improved cusp washout and reduced loading |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4878906A (en) * | 1986-03-25 | 1989-11-07 | Servetus Partnership | Endoprosthesis for repairing a damaged vessel |
US4676229A (en) * | 1986-04-09 | 1987-06-30 | Welch Allyn, Inc. | Biopsy channel for an endoscope |
US5019090A (en) * | 1988-09-01 | 1991-05-28 | Corvita Corporation | Radially expandable endoprosthesis and the like |
US4950227A (en) * | 1988-11-07 | 1990-08-21 | Boston Scientific Corporation | Stent delivery system |
US5123917A (en) * | 1990-04-27 | 1992-06-23 | Lee Peter Y | Expandable intraluminal vascular graft |
WO1991017724A1 (en) * | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
US5360443A (en) * | 1990-06-11 | 1994-11-01 | Barone Hector D | Aortic graft for repairing an abdominal aortic aneurysm |
DE9117152U1 (en) * | 1990-10-09 | 1996-07-11 | Cook Inc | Stent |
JPH0717314Y2 (en) * | 1990-10-18 | 1995-04-26 | ソン ホーヨン | Self-expanding intravascular stent |
US5163951A (en) * | 1990-12-27 | 1992-11-17 | Corvita Corporation | Mesh composite graft |
US5135536A (en) * | 1991-02-05 | 1992-08-04 | Cordis Corporation | Endovascular stent and method |
US5366504A (en) * | 1992-05-20 | 1994-11-22 | Boston Scientific Corporation | Tubular medical prosthesis |
US5316023A (en) * | 1992-01-08 | 1994-05-31 | Expandable Grafts Partnership | Method for bilateral intra-aortic bypass |
US5562725A (en) * | 1992-09-14 | 1996-10-08 | Meadox Medicals Inc. | Radially self-expanding implantable intraluminal device |
BE1006440A3 (en) * | 1992-12-21 | 1994-08-30 | Dereume Jean Pierre Georges Em | Luminal endoprosthesis AND METHOD OF PREPARATION. |
ES2170093T3 (en) * | 1993-01-14 | 2002-08-01 | Meadox Medicals Inc | RADIAL EXPANDABLE TUBULAR PROTESIS. |
US5643309A (en) * | 1993-03-25 | 1997-07-01 | Myler; Richard | Cardiovascular stent and retrieval apparatus |
US5527353A (en) * | 1993-12-02 | 1996-06-18 | Meadox Medicals, Inc. | Implantable tubular prosthesis |
JP2703510B2 (en) * | 1993-12-28 | 1998-01-26 | アドヴァンスド カーディオヴァスキュラー システムズ インコーポレーテッド | Expandable stent and method of manufacturing the same |
US5476506A (en) * | 1994-02-08 | 1995-12-19 | Ethicon, Inc. | Bi-directional crimped graft |
US5683451A (en) * | 1994-06-08 | 1997-11-04 | Cardiovascular Concepts, Inc. | Apparatus and methods for deployment release of intraluminal prostheses |
DE69518435T3 (en) * | 1994-06-08 | 2004-07-22 | CardioVascular Concepts, Inc., Portola Valley | A branching graft manufacturing system |
EP0689805B1 (en) * | 1994-06-27 | 2003-05-28 | Corvita Corporation | Bistable luminal graft endoprostheses |
US5522883A (en) * | 1995-02-17 | 1996-06-04 | Meadox Medicals, Inc. | Endoprosthesis stent/graft deployment system |
-
1996
- 1996-06-26 US US08/668,345 patent/US5843161A/en not_active Expired - Lifetime
-
1997
- 1997-06-03 CA CA002206743A patent/CA2206743C/en not_active Expired - Lifetime
- 1997-06-25 EP EP97304514A patent/EP0815805B1/en not_active Expired - Lifetime
- 1997-06-25 DE DE69738006T patent/DE69738006T2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0815805B1 (en) | 2007-08-15 |
DE69738006D1 (en) | 2007-09-27 |
US5843161A (en) | 1998-12-01 |
EP0815805A2 (en) | 1998-01-07 |
CA2206743A1 (en) | 1997-12-26 |
DE69738006T2 (en) | 2008-05-08 |
EP0815805A3 (en) | 1999-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2206743C (en) | Endoprosthesis assembly for percutaneous deployment and method of deploying same | |
CA2209880C (en) | Low profile, thermally set wrapped cover for a percutaneously deployed stent | |
CA2141917C (en) | Bi-directional crimped graft | |
US6533807B2 (en) | Radially-expandable stent and delivery system | |
US6582472B2 (en) | Kinetic stent | |
EP1073384B1 (en) | Low profile stent and graft combination | |
JP4426182B2 (en) | Deployment system for in-vessel devices | |
US6929659B2 (en) | Method of preventing the dislodgment of a stent-graft | |
CA2173664C (en) | Self-expanding stent for a medical device to be introduced into a cavity of a body | |
US5849037A (en) | Self-expanding stent for a medical device to be introduced into a cavity of a body, and method for its preparation | |
US5403341A (en) | Parallel flow endovascular stent and deployment apparatus therefore | |
MXPA01002910A (en) | Method and apparatus for covering a stent. | |
CA2346164A1 (en) | Guidewire capture device | |
EP0836449A1 (en) | Prosthetic graft and method for aneurysm repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20170605 |